Posted: Tuesday, March 19, 2013 1:09 PM ET
It’s our hope to provide explosive gains as we head into ASCO 2013, or the American Society of Clinical Oncology meeting held every year.
Every one knows nothing has the power to send a biotech to the moon like the FDA.
Unless that biotech is presenting at the annual American Society of Clinical Oncology Conference (ASCO)…
Any time a company is expected to present positive data at ASCO, the speculation over FDA approval, buyout, and game-changing findings can jet stock prices going into the conference.
For 2012’s ASCO conference, we took a position in Celldex (CLDX) shortly before it popped from $3 to more than $4… and before its run to $9.
Those gains were simply realized on the ASCO conference hype.
In 2011, we bought our favorite prostate drug stock, Dendreon (DNDN) and watched it explode from $35 to $55.
Heading into the 2010 ASCO conference, we took a position in Delcath (DCTH), for example. It would run from a low of about $6 to more than $16 before selling off after the event.
Does this mean ASCO stocks run every time, every year?
Don't miss out on the most important market news delivered daily to your inbox every market morning for FREE!
About Market Intelligence Center |
Contact Us |
Terms of Service
Investors Observer |
Market Intelligence Center |
Fresh Brewed Media News |
S&P Option Strategies |
Fresh Brewed Media
Portions of this content may be copyright by Fresh Brewed Media, Investors Observer, and/or O2 Media LLC. Portions of this content are protected by the following US Patents: 7,716,116; 7,856,390; 7,865,496; 8,463,695; 8,494,944; and 8,676,691.